Document Detail


Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors.
MedLine Citation:
PMID:  23078830     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
ROP remains a major cause of childhood blindness worldwide. The smallest, sickest infants develop the most severe forms of zone 1 ROP. Such eyes may not be successfully treated by near confluent laser to the avascular retina (current standard of care). With an understanding of ROP pathogenesis, vascular endothelial growth factor inhibitors (anti-VEGF) are being given only when VEGF is elevated in retina and vitreous. Careful screening allows proper timing of administration. Ideal dose (perhaps different for mild and severe cases) and drug (interrupting only pathologic neovascularization and not normal angiogenesis) remain unproven. The author discusses controversial use of anti-VEGF with documented efficacy, observed local complications, and potential systemic toxicities (none observed in six years) to allow retention of vision for severe zone 1 ROP. The benefits have been demonstrated, however, local and systemic risks in these developing premature infants must be carefully studied (both short and long term).
Authors:
Helen A Mintz-Hittner
Publication Detail:
Type:  Journal Article     Date:  2012-10-15
Journal Detail:
Title:  Early human development     Volume:  88     ISSN:  1872-6232     ISO Abbreviation:  Early Hum. Dev.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-04-11     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7708381     Medline TA:  Early Hum Dev     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  937-41     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Ophthalmology and Visual Science, University of Texas Health Science Center, Houston Medical School, 6400 Fannin Street, Suite 1800, Houston, TX 77030-1526, USA. Helen.A.Mintz-Hittner@uth.tmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Humanized / adverse effects,  therapeutic use
Aptamers, Nucleotide / adverse effects,  therapeutic use
Humans
Infant
Infant, Newborn
Infant, Premature
Receptors, Vascular Endothelial Growth Factor / adverse effects,  therapeutic use
Recombinant Fusion Proteins / adverse effects,  therapeutic use
Retinopathy of Prematurity / diagnosis,  drug therapy*,  physiopathology
Vascular Endothelial Growth Factors / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Recombinant Fusion Proteins; 0/Vascular Endothelial Growth Factors; 0/pegaptanib; 0/ranibizumab; 15C2VL427D/aflibercept; 2S9ZZM9Q9V/bevacizumab; EC 2.7.10.1/Receptors, Vascular Endothelial Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of the mandibular ramus fracture line after sagittal split ramus osteotomy using 3-dimens...
Next Document:  White matter injury following fetal inflammatory response syndrome induced by chorioamnionitis and f...